1974
Treatment of malignant melanoma with methyl CCNU
Young R, Canellos G, Chabner B, Schein P, Brereton H, DeVita V. Treatment of malignant melanoma with methyl CCNU. Clinical Pharmacology & Therapeutics 1974, 15: 617-622. PMID: 4601745, DOI: 10.1002/cpt1974156617.Peer-Reviewed Original Research
1973
MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSION
Young R, Chabner B, Canellos G, Schein P, Devita V. MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSION. The Lancet 1973, 301: 1339-1343. PMID: 4122739, DOI: 10.1016/s0140-6736(73)91672-3.Peer-Reviewed Original ResearchConceptsMaintenance therapyIntermittent therapyAdvanced HodgkinMaintenance chemotherapyAdditional therapyComplete remissionInitial remissionMedian durationFurther therapyHodgkin's diseasePatientsTherapyRemissionEntire groupDiseaseChemotherapySignificant differencesSurvivalGroupPrednisoneRegimensComplicationsMustineVincristineInfectionPhysiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man
Sponzo R, Devita V, Oliverio V. Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man. Cancer 1973, 31: 1154-1159. PMID: 4705152, DOI: 10.1002/1097-0142(197305)31:5<1154::aid-cncr2820310517>3.0.co;2-b.Peer-Reviewed Original ResearchInitial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu)
Young R, Walker M, Canellos G, Schein P, Chabner B, Devita V. Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu). Cancer 1973, 31: 1164-1169. PMID: 4705154, DOI: 10.1002/1097-0142(197305)31:5<1164::aid-cncr2820310519>3.0.co;2-4.Peer-Reviewed Original ResearchMeSH KeywordsCyclohexanesEvaluation Studies as TopicHematopoietic SystemHumansLeukopeniaNeoplasmsNitrosourea CompoundsThrombocytopeniaConceptsPrior therapyMultiple dosesClinical trialsCumulative marrow toxicityObjective therapeutic responseHepatic side effectsSingle oral doseReticulum cell sarcomaInitial clinical trialsPrimary brain tumorsPreliminary clinical trialsMarrow suppressionHodgkin's diseaseOral doseCell sarcomaMarrow toxicityPrimary toxicityTherapeutic responseBrain tumorsSide effectsPatientsConsiderable toxicitySubsequent courseMeCCNUDoses
1972
THE EFFECT OF CHEMOTHERAPY ON THE GROWTH OF LEUKEMIA L1210 II. PERSISTENCE OF A NITROSOUREA‐INDUCED CHANGE IN THE GROWTH CHARACTERISTICS OF TRANSPLANT GENERATIONS
DeVita V, Bray D, Bostick F, Bagley C. THE EFFECT OF CHEMOTHERAPY ON THE GROWTH OF LEUKEMIA L1210 II. PERSISTENCE OF A NITROSOUREA‐INDUCED CHANGE IN THE GROWTH CHARACTERISTICS OF TRANSPLANT GENERATIONS. Cell Proliferation 1972, 5: 459-466. PMID: 4654583, DOI: 10.1111/j.1365-2184.1972.tb00384.x.Peer-Reviewed Original ResearchTreatment of the lymphomas.
DeVita V, Canellos G. Treatment of the lymphomas. Seminars In Hematology 1972, 9: 193-209. PMID: 4111886.Peer-Reviewed Original Research
1971
Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU
Young R, DeVita V, Serpick A, Canellos G. Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU. New England Journal Of Medicine 1971, 285: 475-479. PMID: 5558887, DOI: 10.1056/nejm197108262850902.Peer-Reviewed Original ResearchEffects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle.
Bray D, DeVita V, Adamson R, Oliverio V. Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle. Cancer Chemotherapy Reports 1971, 55: 215-20. PMID: 5115843.Peer-Reviewed Original Research